Literature DB >> 14740870

Inducible nitric oxide synthase (NOS2) promoter CCTTT repeat polymorphism: relationship to in vivo nitric oxide production/NOS activity in an asymptomatic malaria-endemic population.

Craig S Boutlis1, Maurine R Hobbs, Robyn L Marsh, Mary A Misukonis, Ariana N Tkachuk, Moses Lagog, Jennifer Booth, Donald L Granger, Moses J Bockarie, Charles S Mgone, Marc C Levesque, J Brice Weinberg, Nicholas M Anstey.   

Abstract

Polymorphisms in the inducible nitric oxide synthase gene (NOS2) promoter have been associated with clinical outcome from malaria. These include a CCTTT repeat (CCTTTn) 2.5 kilobases upstream from the NOS2 transcription start site, and two single nucleotide substitutions: G-->C at position -954 (G-954C), and C-->T at position -1173 (C-1173T). Although hypothesized to influence NO production in vivo, the functional relevance of (CCTTT)n and G-954C is uncertain because disease association studies have yielded inconsistent results. This study found no association between CCTTT repeat number and levels of plasma NO metabolites or peripheral blood mononuclear cell NOS activity in a cohort of asymptomatic malaria-exposed coastal Papua New Guineans 1-60 years old. This suggests that (CCTTT)n does not independently influence NOS2 transcription in vivo. Neither the G-954C nor the C-1173T polymorphisms were identified in this population, indicating the variability and complexity of selection for NOS2 promoter polymorphisms in different malaria-endemic populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14740870

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.

Authors:  Michael Hawkes; Robert Opika Opoka; Sophie Namasopo; Christopher Miller; Andrea L Conroy; Lena Serghides; Hani Kim; Nisha Thampi; W Conrad Liles; Chandy C John; Kevin C Kain
Journal:  Med Hypotheses       Date:  2011-07-13       Impact factor: 1.538

Review 2.  Malaria tolerance--for whom the cell tolls?

Authors:  Craig S Boutlis; Tsin W Yeo; Nicholas M Anstey
Journal:  Trends Parasitol       Date:  2006-06-19

3.  Nitric oxide production and nitric oxide synthase activity in malaria-exposed Papua New Guinean children and adults show longitudinal stability and no association with parasitemia.

Authors:  Craig S Boutlis; J Brice Weinberg; Joanne Baker; Moses J Bockarie; Charles S Mgone; Qin Cheng; Nicholas M Anstey
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

4.  Gastric cancer is associated with NOS2 -954G/C polymorphism and environmental factors in a Brazilian population.

Authors:  Yvana C Jorge; Marcia C Duarte; Ana E Silva
Journal:  BMC Gastroenterol       Date:  2010-06-17       Impact factor: 3.067

5.  Malaria severity and human nitric oxide synthase type 2 (NOS2) promoter haplotypes.

Authors:  Marc C Levesque; Maurine R Hobbs; Charles W O'Loughlin; Jennifer A Chancellor; Youwei Chen; Ariana N Tkachuk; Jennifer Booth; Kistie B Patch; Sallie Allgood; Ann R Pole; Carolyn A Fernandez; Esther D Mwaikambo; Theonest K Mutabingwa; Michal Fried; Bess Sorensen; Patrick E Duffy; Donald L Granger; Nicholas M Anstey; J Brice Weinberg
Journal:  Hum Genet       Date:  2009-10-27       Impact factor: 4.132

6.  The CCTTT pentanucleotide microsatellite in iNOS promoter influences the clinical outcome in P. falciparum infection.

Authors:  G Dhangadamajhi; B N Mohapatra; S K Kar; M R Ranjit
Journal:  Parasitol Res       Date:  2009-01-20       Impact factor: 2.289

7.  NOS2 variants reveal a dual genetic control of nitric oxide levels, susceptibility to Plasmodium infection, and cerebral malaria.

Authors:  Maria de Jesus Trovoada; Madalena Martins; Riadh Ben Mansour; Maria do Rosário Sambo; Ana B Fernandes; Lígia Antunes Gonçalves; Artur Borja; Roni Moya; Paulo Almeida; João Costa; Isabel Marques; M Paula Macedo; António Coutinho; David L Narum; Carlos Penha-Gonçalves
Journal:  Infect Immun       Date:  2013-12-30       Impact factor: 3.441

8.  Inhaled nitric oxide for the adjunctive therapy of severe malaria: protocol for a randomized controlled trial.

Authors:  Michael Hawkes; Robert O Opoka; Sophie Namasopo; Christopher Miller; Kevin E Thorpe; James V Lavery; Andrea L Conroy; W Conrad Liles; Chandy C John; Kevin C Kain
Journal:  Trials       Date:  2011-07-13       Impact factor: 2.279

9.  NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity.

Authors:  Yasushi Kawaguchi; Akiko Tochimoto; Masako Hara; Manabu Kawamoto; Tomoko Sugiura; Yasuhiro Katsumata; Jun Okada; Hirobumi Kondo; Mitsuo Okubo; Naoyuki Kamatani
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

10.  Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms.

Authors:  Stéphanie Bibert; Martin W Bratschi; Samuel Y Aboagye; Emilie Collinet; Nicole Scherr; Dorothy Yeboah-Manu; Christian Beuret; Gerd Pluschke; Pierre-Yves Bochud
Journal:  Front Microbiol       Date:  2017-10-04       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.